Related Experiment Video
Updated: May 5, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.7K
Real-World Experience With Control-IQ Technology in Saudi Children With Insulin-Dependent Diabetes: A Single-Center
Afaf Alsagheir1,2, Bassam Bin-Abbas1,2, Razan Alsagheir1
1Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, kfshrc.edu.sa.
Pediatric Diabetes
|March 4, 2026
Summary
The Tandem t:slim X2 insulin pump with Control-IQ technology significantly improved glycemic control in Saudi children with diabetes, reducing HbA1c and hypoglycemia. This automated insulin delivery system demonstrated high efficacy and safety in a real-world clinical setting.
Area of Science:
- Pediatric Endocrinology
- Diabetes Technology
- Metabolic Disorders
Background:
- Automated insulin delivery (AID) systems like the Tandem t:slim X2 with Control-IQ technology offer advanced glycemic management.
- Limited data exists on Control-IQ efficacy in Saudi pediatric and young adult populations previously on multiple daily injections (MDIs).
Purpose of the Study:
- To evaluate the efficacy and safety of Control-IQ technology in children with insulin-dependent diabetes transitioning from MDIs.
- To assess the primary outcome of HbA1c change at 6 months post-initiation of Control-IQ therapy.
Main Methods:
- Prospective observational study involving 100 children (aged 2-14 years) with insulin-dependent diabetes in Saudi Arabia.
- Patients transitioned from multiple daily injections (MDIs) to the Control-IQ technology.
- Data collected at King Faisal Specialist Hospital and Research Centre (KFSHRC).
Main Results:
- Median HbA1c decreased significantly from 9.2% to 6.9% at 6 months (p < 0.001).
- Time in Range (TIR) improved from 45.6% to 68.8% (p < 0.001), while severe hypoglycemia decreased by 88.9% (p < 0.001).
- High adherence was observed, with no severe hypoglycemia or discontinuations; 3% experienced mild/moderate ketoacidosis.
Conclusions:
- Control-IQ technology is effective and safe for improving glycemic outcomes in children with insulin-dependent diabetes in a real-world setting.
- Successful implementation necessitates comprehensive patient training and ongoing support.
- The study provides crucial data for Saudi pediatric diabetes management.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:12Type I Diabetes I: Introduction
45
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
45
01:19Type I Diabetes III: Clinical Manifestations
26
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
26
01:26Type II Diabetes I: Introduction
17
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
01:25Diabetic Ketoacidosis l: Introduction
30
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic...
30